HDM201 + cytarabine + liposomal cytarabine + liposomal daunorubicin

HDM201 + cytarabine + liposomal cytarabine + liposomal daunorubicin is a four-drug combination regimen investigated for the treatment of hematological malignancies, particularly acute myeloid leukemia (AML). The components have distinct mechanisms: - **HDM201** is a selective small-molecule inhibitor of the MDM2-p53 interaction, leading to activation of the p53 tumor suppressor pathway and apoptosis in p53 wild-type cancer cells. - **Cytarabine** is a pyrimidine nucleoside analog that inhibits DNA synthesis, resulting in cell cycle arrest and apoptosis of rapidly dividing cells. - **Liposomal cytarabine** improves plasma stability and CNS penetration by encapsulation in liposomes, prolonging cytarabine exposure. - **Liposomal daunorubicin** is an anthracycline encapsulated in liposomes to target tumor tissue with reduced toxicity; it intercalates into DNA and inhibits topoisomerase II, leading to DNA damage and cell death. This multi-agent chemotherapy approach is designed to maximize antileukemic efficacy by combining direct cytotoxicity with targeted inhibition of oncogenic signaling.